darovasertib   Click here for help

GtoPdb Ligand ID: 11186

Synonyms: Example 9 [WO2016020864A1] | IDE-196 | IDE196 | LXS-196 | LXS196 | NVP-LXS196
PDB Ligand
Compound class: Synthetic organic
Comment: Darovasertib (LXS196) is an oral protein kinase C (PKC) inhibitor that was developed by Novartis for antineoplastic potential. It is one of the chemical structures claimed in Novartis' patent WO2016020864A1 [1]. Darovasertib is a potential first-in-class protein kinase C (PKC) inhibitor.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 135.94
Molecular weight 472.19
XLogP 2.7
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(c1nc(cnc1N)c1ncccc1C(F)(F)F)Nc1ncccc1N1CCC(CC1)(C)N
Isomeric SMILES O=C(c1nc(cnc1N)c1ncccc1C(F)(F)F)Nc1ncccc1N1CCC(CC1)(C)N
InChI InChI=1S/C22H23F3N8O/c1-21(27)6-10-33(11-7-21)15-5-3-9-29-19(15)32-20(34)17-18(26)30-12-14(31-17)16-13(22(23,24)25)4-2-8-28-16/h2-5,8-9,12H,6-7,10-11,27H2,1H3,(H2,26,30)(H,29,32,34)
InChI Key XXJXHXJWQSCNPX-UHFFFAOYSA-N
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
protein kinase C theta Hs Inhibitor Inhibition 9.4 pIC50 - 1
pIC50 9.4 (IC50 4x10-10 M) [1]
protein kinase C alpha Hs Inhibitor Inhibition 8.7 pIC50 - 1
pIC50 8.7 (IC50 1.9x10-9 M) [1]